Skip to content

Trial Summary

This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.



ACTRN/NCT /ethics:


Scientific title:

A Phase I, First-in-Human, Open-Label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumors

Sponsor / Cooperative group:

LaNova Medicines

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years to 75 years
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2021-05-17
Anticipated End Date2023-02-28

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal Investigator-
Recruitment StatusRecruiting